PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancerNorman Fultang(Incyte (United States)), Neha Bhagwat(Resolve Therapeutics (United States))Frontiers in OncologyFebruary 2, 202410.3389/fonc.2024.1343004Cited by 5SaveCiteExport RISWatch citationsRelated PapersLeukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation|Cancer Cell|2010|2.7kROR1 regulates chemoresistance in Breast Cancer via modulation of drug efflux pump ABCB1|Scientific Reports|2020|59